Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
S
Saddekar, Shraddha
Genentech, Inc.
(
T1430-02-08
)
Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Shraddha Saddekar
Favorite
Sarkar, Tanoy
California Northstate University
(
W1030-01-04
)
Preparation and Scale-Up of Liposomal Amphotericin B Formulation and a Comparison with Commercially Available Counterpart, Ambisome®
Tanoy Sarkar
Favorite
Sarvaiya, Hetal
Abbvie
(
T1430-02-10
)
A Novel In Vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards
Hetal Sarvaiya
Favorite
Sastry, Skanda
Genentech, Inc.
(
T1430-01-03
)
Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Skanda Sastry
Favorite
Sauve, Zacharie
Certara
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Zacharie Sauve
Favorite
Scapin, Giovana
Nanoimaging Services
(
W1330-02-09
)
Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Giovana Scapin
Favorite
Schartner, Jill
Genentech, Inc.
(
T1130-02-07
)
Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Jill Schartner
Favorite
Schimmel, Margaret
University of California Santa Barbara
(
W1430-02-07
)
Novel Use of Recombinant Dimeric IgA Monoclonal Antibodies as Cyst-Targeted Therapeutics in Polycystic Kidney Disease
Margaret Schimmel
Favorite
Schlesinger, Erica
Seran Biosciences
(
W1430-01-02
)
High Concentration Protein Suspensions: A Case Study for Subcutaneous Delivery of Bevacizumab
Erica Schlesinger
Favorite
Schneider, Thomas
BioAgilytix Labs
(
W1230-02-10
)
Qualification of a 48-plex Cytokine Olink Panel to Support Rare Disease and Pediatric Clinical Studies
Thomas Schneider
Favorite
Schwartz, Daniel
University of Colorado Boulder
(
W1330-01-01
)
Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Daniel Schwartz
Favorite
Selen, Ebru
SCIEX
(
T1430-02-07
)
Analysis of Glucagon-Like Peptide-1 (GLP-1) Analog in Rat Plasma Using an LC-MS/MS Workflow
Ebru Selen
Favorite
Sellin, Mikael
Uppsala University
(
W1030-02-08
)
Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Mikael Sellin
Favorite
Senda, Masaaki
Sawai Pharmaceutical Co., Ltd.
(
T1230-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Masaaki Senda
Favorite
(
T1430-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Masaaki Senda
Favorite
(
W1130-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Masaaki Senda
Favorite
(
W1330-02-06
)
Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Masaaki Senda
Favorite
Seshadri, Soorya
EpiVax, Inc.
(
T1130-02-11
)
Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Soorya Seshadri
Favorite
Shearer-Kang, Esther
Genentech, Inc.
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Esther Shearer-Kang
Favorite
Shen, Ben-Quan
Genentech, Inc.
(
T1530-02-07
)
Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Ben-Quan Shen
Favorite
Sheng, Xinyi
Georgia Institute of Technology
(
W1330-01-03
)
Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
Xinyi Sheng
Favorite
Shen, Yue
University of Cincinnati
(
W1030-01-03
)
Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
Yue Shen
Favorite
Shih, Shian-Jiun
Cellentia, Inc.
(
T1330-02-10
)
Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Shian-Jiun Shih
Favorite
(
W1430-02-08
)
In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Shian-Jiun Shih
Favorite
Shim, Jeongsup
Genentech, Inc.
(
T1330-02-09
)
Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Jeongsup Shim
Favorite
Shivva, Vittal
Genentech, Inc.
(
T1530-02-07
)
Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Vittal Shivva
Favorite
Shi, Wenting
Georgia Institute of Technology
(
W1330-01-03
)
Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
Wenting Shi
Favorite
Shukla, Jaya
Post Graduate Institute of Medical Education and Research
(
W1530-02-08
)
Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Jaya Shukla
Favorite
Siddhanta, Kasturi
University of Nebraska Medical Center
(
T1230-01-05
)
Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Kasturi Siddhanta
Favorite
Siguenza, Patricia
Genentech, Inc.
(
T1530-02-08
)
Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Patricia Siguenza
Favorite
Singh, Gurpal
Panjab University
(
W1230-02-07
)
Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Gurpal Singh
Favorite
Singh, Jasmine
Gyros Protein Technologies
(
T1330-02-11
)
Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
Jasmine Singh
Favorite
(
T1530-02-10
)
Development of a Generic, Automated, Microfluidic Human IgG-FcRn Affinity Assay In-Solution for Use in Antibody Engineering
Jasmine Singh
Favorite
(
W1130-02-11
)
Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Jasmine Singh
Favorite
Singh, Joga
Panjab University
(
W1230-02-07
)
Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Joga Singh
Favorite
Sinko, Balint
Pion Inc.
(
T1030-01-02
)
Demonstrating the Excipient Effect In Vitro for Pre-clinical Formulation Analysis
Balint Sinko
Favorite
Siradze, Ketevan
Genentech, Inc.
(
T1330-02-09
)
Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Ketevan Siradze
Favorite
Somaida, Ahmed
Philipps University of Marburg
(
T1130-02-08
)
Intestinal Organoid as a Predictive Model for the Assessment of Nano-Drug Delivery Systems
Ahmed Somaida
Favorite
Sotomayor Albino, Anais
BioAgilytix Labs
(
W1530-02-09
)
Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Anais Sotomayor Albino
Favorite
Sperinde, Gizette
Genentech, Inc.
(
T1330-02-09
)
Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Gizette Sperinde
Favorite
(
W1130-02-10
)
Choosing the Right Bioanalytical Platform to Accommodate a Biotherapeutic Pharmacokinetic Measurement in Serum and CSF: A Case Study
Gizette Sperinde
Favorite
Spiciarich, David R.
AstraZeneca
(
W1230-02-09
)
LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
David R. Spiciarich
Favorite
Spinosa, Phillip
Genentech, Inc.
(
T1130-02-07
)
Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Phillip Spinosa
Favorite
Spytko, Adriane
Q Squared Solutions
(
W1430-02-09
)
Exploring the Future Potentials of High-Resolution Mass Spectrometry for Regulated Bioanalysis
Adriane Spytko
Favorite
Stachura, Nina
Merck & Co., Inc.
(
W1330-02-11
)
One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Nina Stachura
Favorite
Stefanich, Eric
Genentech, Inc.
(
T1430-02-08
)
Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Eric Stefanich
Favorite
Stevenson, Joseph
Merck Sharp & Dohme Corp.
(
W1330-02-07
)
Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Joseph Stevenson
Favorite
Storey, Kristine
Merck & Co., Inc.
(
T1530-02-09
)
False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Kristine Storey
Favorite
Subramanian, Kalyanasundaram
Differentia Bio
(
T1030-02-06
)
A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Kalyanasundaram Subramanian
Favorite
Sugano, Yukihito
Astellas Pharma Inc.
(
T1330-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Yukihito Sugano
Favorite
(
W1230-01-01
)
Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Yukihito Sugano
Favorite
Sule, Olagoke
Genentech, Inc.
(
T1430-02-09
)
Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Olagoke Sule
Favorite
Sun, Di
AliveX Biotech
(
T1030-02-06
)
A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Di Sun
Favorite
Sun, Li
Merck Sharp & Dohme Corp.
(
W1330-02-07
)
Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Li Sun
Favorite
Sun, Ruimin
AliveX Biotech
(
T1030-02-06
)
A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Ruimin Sun
Favorite
Surface, Morgan
West Virginia University
(
T1430-01-04
)
Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Morgan Surface
Favorite
Swanson, Steven
Genentech, Inc.
(
T1330-02-07
)
Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Steven Swanson
Favorite
